文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

早期血管内事件与急性呼吸窘迫综合征发生相关:LIPS-A 临床试验亚组研究

Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01
一句话结论在 ARDS 高危患者中,基线血管内单核细胞活化生物标志物与 ARDS 发生相关;早期阿司匹林预防 ARDS 的潜在临床获益仍不确定。

该研究为多中心、双盲阿司匹林 versus 安慰剂临床试验(LIPS-A,NCT01504867)的亚组分析,纳入 ARDS 高危患者,检测入组时及用药后血浆血栓素 B2(TXB2)、阿司匹林触发的脂氧素 A4(15-epi-LXA4,ATL)及外周血白细胞数量与活化。367 例受试者中 33 例(9.0%)随机化后发生 ARDS。基线 ATL 水平、总单核细胞计数、中间型单核细胞计数及单核细胞-血小板聚集体与 ARDS 发生相关。外周血中性粒细胞计数及单核细胞-血小板聚集体随时间显著下降。9 例在随机化后、研究药物启动前发生 ARDS,其中 7 例分配至阿司匹林组。首次给药时无 ARDS 的受试者中,阿司匹林治疗组 ARDS 发生率较低。与安慰剂相比,阿司匹林显著降低 TXB2 并升高 ATL/TXB2 比值。

要点

  • 367 例 ARDS 高危受试者中 33 例(9.0%)随机化后发生 ARDS。
  • 基线 ATL 水平、总单核细胞计数、中间型单核细胞计数及单核细胞-血小板聚集体与 ARDS 发生相关。
  • 9 例在随机化后、研究药物启动前发生 ARDS,其中 7 例分配至阿司匹林组。
  • 首次给药时无 ARDS 的受试者中,阿司匹林治疗组 ARDS 发生率较低。
  • 与安慰剂相比,阿司匹林显著降低 TXB2 并升高 ATL/TXB2 比值。

适用人群与场景

  • ARDS 高危患者,纳入多中心、双盲阿司匹林 versus 安慰剂临床试验(LIPS-A,NCT01504867)。

处置流程与药物剂量

  • 受试者随机接受阿司匹林或安慰剂治疗;原文未报告具体剂量、给药途径与疗程。

研究设计与关键结果

  • 研究类型为多中心、双盲临床试验的亚组研究;367 例受试者中 33 例(9.0%)随机化后发生 ARDS。
  • 基线 ATL 水平、总单核细胞计数、中间型单核细胞计数及单核细胞-血小板聚集体与 ARDS 发生相关。
  • 外周血中性粒细胞计数及单核细胞-血小板聚集体随时间显著下降。
  • 9 例在随机化后、研究药物启动前发生 ARDS,其中 7 例分配至阿司匹林组。
  • 首次给药时无 ARDS 的受试者中,阿司匹林治疗组 ARDS 发生率较低。
  • 与安慰剂相比,阿司匹林显著降低 TXB2 并升高 ATL/TXB2 比值。

证据类型、等级与局限

  • 证据类型:多中心、双盲随机对照临床试验(LIPS-A,NCT01504867)的亚组研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,高危患者血管内单核细胞活化生物标志物与 ARDS 发生相关,早期阿司匹林预防 ARDS 的潜在临床获益仍不确定;生化与免疫分析结果为了解人 ARDS 早期发病机制提供了窗口,并可能是 ARDS 风险的潜在血管生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies.

OBJECTIVES: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS.

METHODS: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo.

MEASUREMENTS AND MAIN RESULTS: Thirty-three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio.

CONCLUSIONS: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk. Clinical trial registered with www.clinicaltrials.gov (NCT01504867).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Abdulnour RE, Gunderson T, Barkas I, et al. Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial. Am J Respir Crit Care Med. 2018. PMID: 29782179. doi:10.1164/rccm.201712-2530OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。